Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TCMD vs WOK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TCMD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

TCMD Overall Winner 6-Pillar Tally: TCMD 6 – 0 WOK Matrix Metrics: TCMD 8 – 2 WOK

As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TCMD carries a Unified Composite Score of 25.2/100 (SELL) at $26.37 (17.9x Forward P/E, 9.4% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin).

  • Defensive Composite Rating Caution: Although TCMD compares more favorably head-to-head, both TCMD (25.2/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TCMD vs WOK
TCMD NASDAQ Head-to-Head Winner
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$26.37
-1.64% 1D
Market Cap $600.6M
TTM Revenue $356M
Forward P/E 17.9x
Beta / 30D Vol 1.07β · 53% Vol
Unified Composite Score
25.2 / 100 SELL
Tech 50.0 Fund 28.0 Flow 66.0 Mom 21.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.3% over 20 days), RSI 61
RSI-14: 60.7 · SMA20: $24.98 · SMA50: $23.45
WOK NASDAQ
WORK Medical Technology Group LTD Class A Ordinary Shares
Surgical & Medical Instruments & Apparatus
$1.23
+2.5% 1D
Market Cap $5.4M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 38.49β · 153% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 5.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $1.13 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (TCMD 6 – 0 WOK)

Columns: Metric · TCMD · WOK
1. Valuation Multiples TCMD
Forward P/E 17.9x N/M
Trailing P/E 26.0x N/M
PEG Ratio 17.79x N/M
EV / Revenue 1.5x 0.5x
2. Growth & Scale TCMD
Revenue Growth (YoY) +7.1% +19.1%
Earnings Growth (YoY) -13.9% -95.0%
TTM Revenue (USD) $356M $11M
Market Cap $600.6M $5.4M
3. Profitability & Quality TCMD
Gross Margin 77.0% 17.0%
Operating Margin 9.4% -41.7%
Net Profit Margin 6.7% -41.9%
Return on Equity (ROE) 11.0% -19.2%
4. Balance Sheet & Cash Flow TCMD
Cash Generation (TTM) $29M -$3.4M EBITDA
Cash Flow Margin 8.1% -31.4% EBITDA Mgn
Net Cash / Leverage $58M Net Cash $1855.16 Book/Sh · -19.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TCMD
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 54.9% (15th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TCMD
OpEx & R&D Intensity 67.6% of Rev ($241M) 58.7% of Rev ($6.3M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TCMD (8) vs WOK (2)
Institutional Metric TCMD WOK Criterion Row Edge
Market Capitalization
Scale
$600.6M $5.4M Larger Scale TCMD
Trailing P/E Ratio
Valuation
26.0x N/M Lower Multiple TCMD
Forward P/E Ratio
Valuation
17.9x N/M Lower Multiple TCMD
Revenue Growth (YoY)
Growth
+7.1% +19.1% Higher Growth WOK
Operating Margin (TTM)
Profitability
9.4% -41.7% Higher Margin TCMD
Net Profit Margin
Profitability
6.7% -41.9% Higher Margin TCMD
Return on Equity (ROE)
Capital Efficiency
11.0% -19.2% Higher ROE TCMD
52-Week Range Position
Momentum
34% ($21–$38) 16% ($0–$7) Stronger Trend TCMD
Beta / 30D Volatility
Risk Regime
1.07β · 53% Vol 38.49β · 153% Vol Lower Realized Risk TCMD
Unified Institutional Score
Composite Signal
25.2 / 100 (SELL) 25.6 / 100 (SELL) Higher Composite WOK
Trailing 12M Revenue (USD)
Operating Scale
$356M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.0% 17.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.79x PEG · 1.5x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$29M ($58M Net Cash) -$3.4M EBITDA ($1855.16 Book/Sh · -19.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCMD +4.26 pp
TCMD: +17.1% · WOK: +12.84%
3M Horizon TCMD +54.66 pp
TCMD: +10.57% · WOK: -44.09%
6M Horizon WOK +212.18 pp
TCMD: +11.5% · WOK: +223.68%
1Y Horizon TCMD +80.26 pp
TCMD: +8.21% · WOK: -72.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TCMD vs WOK. Trailing 12-month operating profitability (TCMD 9.4% vs WOK -41.7%) and valuation multiples (TCMD 17.9x vs WOK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TCMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$356M
Gross Margin77.0%
Op. Margin9.4%
ROE / Fwd P/E11.0% · 17.9x
WOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin17.0%
Op. Margin-41.7%
ROE / Fwd P/E-19.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TCMD CONSOLIDATION
94d in phase · OBV ACCUMULATION
Current IV 54.9%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TCMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WOK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TCMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $600.6M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($241M)
90D Engineering Disclosures 0 Published
WOK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.4M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($6.3M)
90D Engineering Disclosures 0 Published

Investor FAQ TCMD vs WOK Key Questions & Quantitative Answers

As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TCMD carries a Unified Composite Score of 25.2/100 (SELL) at $26.37 (17.9x Forward P/E, 9.4% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin). Defensive Composite Rating Caution: Although TCMD compares more favorably head-to-head, both TCMD (25.2/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

TCMD leads the Growth & Scale pillar: TCMD posts +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin), compared with WOK at +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin). On trailing 12-month operating scale, TCMD generates $356M in USD-normalized revenue versus $11M for WOK. In operating R&D and SG&A reinvestment, TCMD deploys 67.6% of Rev ($241M) (0 90-day corporate R&D disclosures) versus 58.7% of Rev ($6.3M) (0 disclosures) for WOK.

TCMD screens cheaper on headline valuation multiples. TCMD trades at 17.9x Forward P/E, 26.0x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin), whereas WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TCMD (11.0% ROE) versus WOK (-19.2% ROE) capital efficiency.

In options market volatility and institutional positioning, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 53% Vol realized risk). By comparison, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (38.49β · 153% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.